Free Trial
→ I was wrong about Trump (From Porter & Company) (Ad)
OTCMKTS:VICP

SSGI 5/15/2023 Earnings Report

SSGI logo
$1.77 0.00 (0.00%)
As of 07/16/2025
ProfileEarnings History

SSGI EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

SSGI Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SSGI Announcement Details

Quarter
Date
5/15/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

SSGI Earnings Headlines

British Science Week - Teaching Resources
November 6, 2024  |  bbc.co.ukhttps://www.bbc.co.uk/teach/articles/zg9c3j6
Best term life insurance: Expert-rated in April 2024
April 28, 2024  |  usatoday.comhttps://www.usatoday.com/money/blueprint/life-insurance/best-term-life-insurance-companies/
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
 |  Porter & Company (Ad)
Anavex Life Sciences Corp AVXL
November 4, 2023  |  morningstar.comM
VICP - Vicapsys Life Sciences, Inc.
August 9, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VICP/history/
ViCapsys files for Nasdaq uplisting, $8M public offering
July 3, 2023  |  msn.comhttps://www.msn.com/en-us/money/markets/vicapsys-files-for-nasdaq-uplisting-8m-public-offering/ar-AA1dnuvr
See More SSGI Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SSGI? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SSGI and other key companies, straight to your email.

About SSGI

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.

View SSGI Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles